Technical services and regulatory affairs consulting group, Diamond Pharma Services, has announced its acquisition of PharmaCentral—a pharmacovigilance services and medical affairs business based in Dublin, Ireland—in an April 22, 2020 press release.
Through the acquisition, Diamond expects to expand its presence in Europe, as well as enhance its senior-level expertise within the company’s pharmacovigilance team. Additionally, the acquisition forms part of Diamond’s growth strategy for its pharmacovigilance division and will ensure the company can support its regulatory affairs business clients in specialist areas, including cell and gene therapies.
“We have seen strong organic growth over the last three years, which has driven us to evaluate our resources, including our in-house expertise, processes, and systems,” said David Boyd, managing director, Diamond PV Services, in the press release. “This acquisition will help support the next phase of growth, representing a step change in our senior team. Having worked closely with PharmaCentral over the past year I am confident that they share our culture of flexibility, quality, and accessibility, and am hugely excited that they are joining Diamond to deliver our shared vision of helping our clients manage their regulatory responsibilities in a constantly evolving environment.”
“This is an incredibly meaningful milestone for PharmaCentral. The cultural fit we have found between the two businesses, and our shared views on the growth areas within pharmacovigilance have created synergistic opportunities for both companies,” added Catherine Kenny, co-founder of PharmaCentral LLP, in the press release. “PharmaCentral has spent a number of years building strong customer relationships and a reputation for quality. Together we will capitalize on those strengths to significantly increase our capabilities and service offerings. The PharmaCentral team is excited to join Diamond Pharma Services and we look forward to the future.”
Source: Diamond Pharma Services